Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge

Citations Over TimeTop 1% of 2017 papers

Abstract

Monoclonal antibodies are one of the fastest growing classes of pharmaceutical products, however, their potential is limited by the high cost of development and manufacturing. Here we present a safe and cost-effective platform for in vivo expression of therapeutic antibodies using nucleoside-modified mRNA. To demonstrate feasibility and protective efficacy, nucleoside-modified mRNAs encoding the light and heavy chains of the broadly neutralizing anti-HIV-1 antibody VRC01 are generated and encapsulated into lipid nanoparticles. Systemic administration of 1.4 mg kg-1 of mRNA into mice results in ∼170 μg ml-1 VRC01 antibody concentrations in the plasma 24 h post injection. Weekly injections of 1 mg kg-1 of mRNA into immunodeficient mice maintain trough VRC01 levels above 40 μg ml-1. Most importantly, the translated antibody from a single injection of VRC01 mRNA protects humanized mice from intravenous HIV-1 challenge, demonstrating that nucleoside-modified mRNA represents a viable delivery platform for passive immunotherapy against HIV-1 with expansion to a variety of diseases.

Related Papers

• → Nucleoside transporters in the disposition and targeting of nucleoside analogs in the kidney(2003)84 cited
• → Formation of nucleoside 5′-polyphosphates from nucleotides and trimetaphosphate(1975)40 cited
• → Preparation of Nucleoside Phosphorothioates, Phosphorodithioates and Related Compounds(1991)15 cited
• → Efficient Synthesis of α‐P‐Modified Nucleoside Triphosphates and Dinucleoside Tetraphosphates via Linear PVPVPIII‐Nucleoside Intermediates(2023)2 cited
• → Nucleoside transport in human and sheep erythrocytes. Evidence that nitrobenzylthioinosine binds specifically to functional nucleoside-transport sites(1980)135 cited